Open AccessEfficacy and safety of anti-angiogenic drugs combined with erlotinib in the treatment of advanced non-small cell lung cancer: a meta-analysis of randomized clinical trials
Author(s) -
Zheng Chen,
Shu Jiang,
Xuechun Li,
Jingyao Zhang,
Liu Liu,
Juan Li,
Peiyu Cao,
Yong Xin,
Longzhen Zhang
Publication year - 2021
Publication title -
annals of palliative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.546
H-Index - 19
eISSN - 2224-5839
pISSN - 2224-5820
DOI - 10.21037/apm-20-1621
Subject(s) - medicine , erlotinib , oncology , lung cancer , adverse effect , subgroup analysis , randomized controlled trial , meta analysis , cochrane library , incidence (geometry) , bevacizumab , epidermal growth factor receptor , cancer , chemotherapy , physics , optics
To determine the efficacy and safety of anti-angiogenic drugs combined with erlotinib in the treatment of advanced non-small cell lung cancer (NSCLC), we performed a meta-analysis of 10 randomized controlled trials (RCTs).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom